Moderna to Offer $2 Billion in Convertibles to Boost Cancer Work

Moderna announced plans to raise $2 billion through convertible debt securities, with proceeds allocated to cancer vaccine development and debt repayment. Convertible securities allow investors to exchange the debt for company shares at a predetermined price. The company did not specify a timeline for the offering.

Next story